Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABX464 maintenance therapy in moderately to severely active ulcerative colitis
ChiCTR2600124664Phase 3Completed
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of obefazimod in autoimmune colitis (3 arms), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoints: clinical remission at week 44, symptomatic remission at week 44 and 1 more. Started May 2026; status: completed.
02
Drugs
obefazimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on ChiCTR2600124664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124664.